Pub Date : 2022-09-12DOI: 10.32756/0869-5490-2022-3-53-58
I. Sabirov, I. Murkamilov, V. Fomin, Z. Murkamilova, A. Sabirova
All patients with chronic kidney disease (CKD) require treatment to reduce the risk of cardiovascular events and to prevent progression of renal failure. ACE inhibitors and angiotensin receptor blockers are widely used for cardio- and nephroprotection in patients with CKD. Sodium glucose cotransporter type 2 (SGLT-2) inhibitors show significant prospects for reducing morbidity and mortality in this population. SGLT-2 inhibitors have been developed for treatment of patients with type 2 diabetes mellitus. However, evidence from multiple randomized clinical trials suggested that these drugs have cardio- and nephroprotective effects in patients with and without diabetes. Despite a wealth of data, SGLT-2 inhibitors remain underused by nephrologists or cardiologists. This is not surprising since new therapies traditionally take decades from research to clinical implementation due to many barriers, including lack of knowledge, concern about drug side effects, lack of decision support, cost, and clinical inertia. The review article presents data from scientific studies on the renoprotective effect of SGLT-2 inhibitors and the mechanisms of this activity in CKD patients.
{"title":"SGLT-2 inhibitors in chronic kidney disease: state of the art","authors":"I. Sabirov, I. Murkamilov, V. Fomin, Z. Murkamilova, A. Sabirova","doi":"10.32756/0869-5490-2022-3-53-58","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-53-58","url":null,"abstract":"All patients with chronic kidney disease (CKD) require treatment to reduce the risk of cardiovascular events and to prevent progression of renal failure. ACE inhibitors and angiotensin receptor blockers are widely used for cardio- and nephroprotection in patients with CKD. Sodium glucose cotransporter type 2 (SGLT-2) inhibitors show significant prospects for reducing morbidity and mortality in this population. SGLT-2 inhibitors have been developed for treatment of patients with type 2 diabetes mellitus. However, evidence from multiple randomized clinical trials suggested that these drugs have cardio- and nephroprotective effects in patients with and without diabetes. Despite a wealth of data, SGLT-2 inhibitors remain underused by nephrologists or cardiologists. This is not surprising since new therapies traditionally take decades from research to clinical implementation due to many barriers, including lack of knowledge, concern about drug side effects, lack of decision support, cost, and clinical inertia. The review article presents data from scientific studies on the renoprotective effect of SGLT-2 inhibitors and the mechanisms of this activity in CKD patients.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77686381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-12DOI: 10.32756/0869-5490-2022-3-38-46
P. Novikov, N. Bulanov, S. Gulyaev, E. Grunina, E. Kuznetsova, T. Shevtsova, S. Moiseev
Psoratic arthritis (PsA) is a common disorder affecting every fifth patient with psoriasis. Typical clinical manifestations of PsA include asymmetric mono/oligoathritis or polyarthritis, spondyloarthritis, enthesitis and dactylitis. More rarely PsA is associated with uveitis and inflammatory bowel disease. Upadacitinib is a selective JAK-kinase inhibitor approved for treatment of PsA. Its efficacy and favorable safety profile in PsA patients were established in two randomized placebocontrolled phase 3 clinical trials (SELECT-PsA 1 and 2). In both studies, upadacitinib was significantly more effective than placebo and improved activity of PsA, psoriatic lesions, enthesitis and dactylitis. Moreover, upadacitinib is approved for treatment of axial spondylitis and, therefore, can be used in patients with any manifestations of PsA. The authors present clinical cases of PsA and discuss indications for upadacitinib administration in such patients.
{"title":"Efficacy and safety of upadacitinib in psoriatic arthritis","authors":"P. Novikov, N. Bulanov, S. Gulyaev, E. Grunina, E. Kuznetsova, T. Shevtsova, S. Moiseev","doi":"10.32756/0869-5490-2022-3-38-46","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-38-46","url":null,"abstract":"Psoratic arthritis (PsA) is a common disorder affecting every fifth patient with psoriasis. Typical clinical manifestations of PsA include asymmetric mono/oligoathritis or polyarthritis, spondyloarthritis, enthesitis and dactylitis. More rarely PsA is associated with uveitis and inflammatory bowel disease. Upadacitinib is a selective JAK-kinase inhibitor approved for treatment of PsA. Its efficacy and favorable safety profile in PsA patients were established in two randomized placebocontrolled phase 3 clinical trials (SELECT-PsA 1 and 2). In both studies, upadacitinib was significantly more effective than placebo and improved activity of PsA, psoriatic lesions, enthesitis and dactylitis. Moreover, upadacitinib is approved for treatment of axial spondylitis and, therefore, can be used in patients with any manifestations of PsA. The authors present clinical cases of PsA and discuss indications for upadacitinib administration in such patients.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88813612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-12DOI: 10.32756/0869-5490-2022-3-22-29
A. Moiseev, E. Mershina, A. Safarova, E. Tao, N. Bulanov, V. Sholomova, Z. Kobalava, E. Pavlikova, S. Moiseev, V. Fomin
To evaluate the frequency and clinical features of heart involvement in Fabry disease (FD) and diagnostic value of cardiac MRI and speckle-tracking echocardiography.
探讨法布里病(FD)心脏受累的频率、临床特征及心脏MRI和斑点跟踪超声心动图的诊断价值。
{"title":"Heart involvement in Fabry disease: clinical features, cardiac MRI and speckle-tracking echocardiography","authors":"A. Moiseev, E. Mershina, A. Safarova, E. Tao, N. Bulanov, V. Sholomova, Z. Kobalava, E. Pavlikova, S. Moiseev, V. Fomin","doi":"10.32756/0869-5490-2022-3-22-29","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-22-29","url":null,"abstract":"To evaluate the frequency and clinical features of heart involvement in Fabry disease (FD) and diagnostic value of cardiac MRI and speckle-tracking echocardiography.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"322 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80273676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-12DOI: 10.32756/0869-5490-2022-3-60-66
G.I. Sirayeva, A. Kolbin, A. Kalyapin, Y. Balykina
To evaluate the socioeconomic burden of paracetamol adverse reactions.
评价扑热息痛不良反应的社会经济负担。
{"title":"The socioeconomic burden of paracetamol adverse reactions over 10 years in Russia","authors":"G.I. Sirayeva, A. Kolbin, A. Kalyapin, Y. Balykina","doi":"10.32756/0869-5490-2022-3-60-66","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-60-66","url":null,"abstract":"To evaluate the socioeconomic burden of paracetamol adverse reactions.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82783605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-12DOI: 10.32756/0869-5490-2022-3-47-52
O. Reshetko, A. I. Grishin
The article presents an overview of studies of pharmaceutical care for patients with different types of headache. Various methods were used, including education of pharmacists, questionnaires for patients and specialists, interviews, the use of special protocols and algorithms for providing pharmaceutical care, patient modelling.
{"title":"Pharmaceutical care for patients with headache: a systematic review of clinical studies","authors":"O. Reshetko, A. I. Grishin","doi":"10.32756/0869-5490-2022-3-47-52","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-47-52","url":null,"abstract":"The article presents an overview of studies of pharmaceutical care for patients with different types of headache. Various methods were used, including education of pharmacists, questionnaires for patients and specialists, interviews, the use of special protocols and algorithms for providing pharmaceutical care, patient modelling.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73273665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-12DOI: 10.32756/0869-5490-2022-3-30-37
S. Moiseev, N. Chebotareva, N. Bulanov, P. Novikov, E. Shchegoleva, T. Shevtsova, E. Tao, E. Filatova
Classic homocystinuria is a rare autosomal recessive disorder of methionine metabolism resulting from a deificiency of cystathionine beta-synthase that is involved in transsulfuration of homocysteine. The disorder is caused by mutations of CBS gene. Lack of enzyme is associated with accumulation of homocysteine that induce various toxicities, e.g. endothelial dysfunction and increased risk of thrombosis. Clinical manifestations of classic homocystinuria include ectopia lentis and/or severe myopia, skeletal abnormalities (marfanoid habitus, generalized osteoporosis and bone deformity), mental retardation, seizures, psychiatric and behavioral disorderts, venous and arterial thrombosis. Some patients with milder form of the disease can present only with thromboembolic events in adulthood. Diagnosis of classic homocystinuria should by established by biochemical (elevated plasma homocysteine and methionine and low cistathione) and genetic (homozygous and compound heterozygous mutations of CBS gene) tests. Low methionine diet, vitamin B6, folic acid and betaine anhydrous, a methylating agent, can be used to reduce homocysteine levels, to prevent progression of the homocystinuria and thromboembolic events.
{"title":"Classic homocystinuria: etiology, natural history and treatment","authors":"S. Moiseev, N. Chebotareva, N. Bulanov, P. Novikov, E. Shchegoleva, T. Shevtsova, E. Tao, E. Filatova","doi":"10.32756/0869-5490-2022-3-30-37","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-30-37","url":null,"abstract":"Classic homocystinuria is a rare autosomal recessive disorder of methionine metabolism resulting from a deificiency of cystathionine beta-synthase that is involved in transsulfuration of homocysteine. The disorder is caused by mutations of CBS gene. Lack of enzyme is associated with accumulation of homocysteine that induce various toxicities, e.g. endothelial dysfunction and increased risk of thrombosis. Clinical manifestations of classic homocystinuria include ectopia lentis and/or severe myopia, skeletal abnormalities (marfanoid habitus, generalized osteoporosis and bone deformity), mental retardation, seizures, psychiatric and behavioral disorderts, venous and arterial thrombosis. Some patients with milder form of the disease can present only with thromboembolic events in adulthood. Diagnosis of classic homocystinuria should by established by biochemical (elevated plasma homocysteine and methionine and low cistathione) and genetic (homozygous and compound heterozygous mutations of CBS gene) tests. Low methionine diet, vitamin B6, folic acid and betaine anhydrous, a methylating agent, can be used to reduce homocysteine levels, to prevent progression of the homocystinuria and thromboembolic events.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79821381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-12DOI: 10.32756/0869-5490-2022-3-16-21
S. Simenyura, Z. Sizova, N. N. Shindryaeva, A.V. Legoshina
To evaluate the impact of various regimens of antihypertensive treatment on blood pressure and target organs in nonadherent hypertensive patients.
目的:评价不同降压治疗方案对非黏附性高血压患者血压及靶器官的影响。
{"title":"Cardio- and nephroprotective effects of antihypertensive therapy in nonadherent hypertensive patients","authors":"S. Simenyura, Z. Sizova, N. N. Shindryaeva, A.V. Legoshina","doi":"10.32756/0869-5490-2022-3-16-21","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-16-21","url":null,"abstract":"To evaluate the impact of various regimens of antihypertensive treatment on blood pressure and target organs in nonadherent hypertensive patients.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81302526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-12DOI: 10.32756/0869-5490-2022-3-9-15
M. Brovko, P. Novikov, E. Nabatchikova, N. Bulanov, E. Tao, P. Potapov, L. Akulkina, N. Soloveva, S. Moiseev
To compare the efficacy of olokizumab and tocilizumab in reducing the risk of invasive mechanical ventilation or death in hospitalized patients with COVID-19.
{"title":"Comparative efficacy of olokizumab and tocilizumab in hospitalized patients with COVID-19","authors":"M. Brovko, P. Novikov, E. Nabatchikova, N. Bulanov, E. Tao, P. Potapov, L. Akulkina, N. Soloveva, S. Moiseev","doi":"10.32756/0869-5490-2022-3-9-15","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-9-15","url":null,"abstract":"To compare the efficacy of olokizumab and tocilizumab in reducing the risk of invasive mechanical ventilation or death in hospitalized patients with COVID-19.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"79 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86833984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-04DOI: 10.32756/0869-5490-2022-2-27-31
R. Aslanova, Z. Kobalava, A. Safarova, M. Vatsik-Gorodetskaya, V. Efimova, E. Cabello Montoya Flora, A. O. Kurlaeva, A. Abramov
Persistent venous congestion in patients with decompensated heart failure (DCHF) increases the risk of rehospitalization and death. VExUS protocol that evaluates the systemic hepatic-renal congestion in addition to assessing the inferior vena cava is regarded as a promising non-invasive ultrasound method to assess venous congestion in these patients.
{"title":"Venous congestion on the VExUS scale in patients with decompensated heart failure","authors":"R. Aslanova, Z. Kobalava, A. Safarova, M. Vatsik-Gorodetskaya, V. Efimova, E. Cabello Montoya Flora, A. O. Kurlaeva, A. Abramov","doi":"10.32756/0869-5490-2022-2-27-31","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-2-27-31","url":null,"abstract":"Persistent venous congestion in patients with decompensated heart failure (DCHF) increases the risk of rehospitalization and death. VExUS protocol that evaluates the systemic hepatic-renal congestion in addition to assessing the inferior vena cava is regarded as a promising non-invasive ultrasound method to assess venous congestion in these patients.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86783930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-04DOI: 10.32756/0869-5490-2022-2-57-62
E. V. Rebrova, E. Shikh, A.Yu. Ryazanovа
Irbesartan belongs to a group of angiotensin II receptor blockers that are used worldwide for the treatment of patients with hypertension, type 2 diabetes, and impaired renal function. Irbesartan can be administered alone or in combination with other antihypertensive drugs (for example, hydrochlorothiazide), if blood pressure control cannot be achieved with monotherapy. The mechanism of action of Irbesartan is mainly due to the selective blockade of AT1 receptors and, as a consequence, a decrease in the vasopressor effect of angiotensin II. The review article summarizes pharmacokinetic and pharmacodynamic properties and clinical data on the tolerability and safety of Irbesartan.
{"title":"Clinical and pharmacological features and place of irbesartan in the treatment of cardiovascular diseases","authors":"E. V. Rebrova, E. Shikh, A.Yu. Ryazanovа","doi":"10.32756/0869-5490-2022-2-57-62","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-2-57-62","url":null,"abstract":"Irbesartan belongs to a group of angiotensin II receptor blockers that are used worldwide for the treatment of patients with hypertension, type 2 diabetes, and impaired renal function. Irbesartan can be administered alone or in combination with other antihypertensive drugs (for example, hydrochlorothiazide), if blood pressure control cannot be achieved with monotherapy. The mechanism of action of Irbesartan is mainly due to the selective blockade of AT1 receptors and, as a consequence, a decrease in the vasopressor effect of angiotensin II. The review article summarizes pharmacokinetic and pharmacodynamic properties and clinical data on the tolerability and safety of Irbesartan.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"261 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75769547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：